Table 2 |
||||||
|
Clinical features of SSc patients. |
||||||
|
Patients |
Age |
Sex |
SSc type |
Early/Late |
Duration (years) |
MRSS |
|
|
||||||
|
N900 |
43 |
F |
||||
|
N901 |
43 |
F |
||||
|
N1003 |
26 |
M |
||||
|
N1016 |
35 |
F |
||||
|
S902 |
54 |
F |
lcSSc |
Early* |
1 |
12 |
|
S903 |
39 |
F |
dcSSc |
Late |
5 |
19 |
|
S904 |
33 |
F |
dcSSc |
Late |
9 |
N/A |
|
S1004 |
27 |
F |
dcSSc |
Late |
10 |
26 |
|
S1066 |
21 |
M |
dcSSc |
Early |
2 |
15 |
|
S1156 |
48 |
F |
SSc/PM |
Early |
1 |
20 |
|
S1302 |
51 |
F |
lcSSc |
Early |
2 |
4 |
|
|
||||||
|
*early = < 2 years from first non-Raynaud symptom at the time of skin biopsy. Fibroblasts from N900-1016 and S902-1004 were used for real-time qPCR analysis. Fibroblasts from S1004-1302 were used for Western blot analysis. MRSS, Modified Rodnan skin score; SSc, systemic sclerosis. |
||||||
|
Fang et al. Arthritis Research & Therapy 2012 14:R229 doi:10.1186/ar4070 |
||||||
